Analysis
Oxford biotech OMass Therapeutics raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings, the company said in a release carried by ValueSpectrum. New investors Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences joined, alongside returning backers Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and the University of Oxford.
Founded in 2016 as a spinout commercializing Oxford professor Dame Carol Robinson's native mass-spectrometry research, OMass uses that platform to study how small molecules bind G-protein-coupled receptors (GPCRs) and other historically hard-to-drug membrane proteins. The company had previously disclosed raising more than $150 million across an extended Series A from backers including Syncona, GV and the British Business Bank — this Series C roughly doubles its disclosed funding.
“It also funds earlier pipeline work, including an SLC15A4 inhibitor for lupus.”
The new capital advances OMS1620, an insurmountable antagonist of the MC2 receptor aimed at rare endocrine disorders including congenital adrenal hyperplasia and Cushing's disease, through Phase 2 development. It also funds earlier pipeline work, including an SLC15A4 inhibitor for lupus. OMass competes in a GPCR-drug-discovery field that includes Structure Therapeutics and Septerna, both of which have also raised large rounds on the thesis that GPCRs, the target class behind roughly a third of all approved drugs, still have plenty of underexploited biology left for new modalities.
The co-lead structure, with three specialist healthcare funds splitting the round rather than one firm taking control, suggests the raise was genuinely competitive rather than an inside rescue. For a company now on its third major financing since 2016, the real test is whether OMS1620's Phase 2 readout in Cushing's disease and congenital adrenal hyperplasia turns a well-capitalized platform story into a company with an approvable asset.
Biotech venture funding has been selective in 2026, concentrated in companies with either late-stage clinical data or a differentiated discovery platform rather than early-stage science alone. OMass's native mass-spectrometry approach to GPCRs is the kind of platform thesis that institutional healthcare investors have continued to back even as overall biotech venture deal count has stayed below its 2021 peak, and the size of this round, among the larger Series C biotech raises disclosed this month, suggests specialist funds still see room to deploy capital into differentiated discovery platforms rather than just clinical-stage assets.